Alligator Bioscience AB (publ)

OM:ATORX BTU Stock Report

Market Cap: SEK 8.7m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Alligator Bioscience Valuation

Is ATORX BTU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of ATORX BTU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate ATORX BTU's fair value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate ATORX BTU's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ATORX BTU?

Key metric: As ATORX BTU is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ATORX BTU. This is calculated by dividing ATORX BTU's market cap by their current revenue.
What is ATORX BTU's PS Ratio?
PS Ratio0.2x
SalesSEK 46.22m
Market CapSEK 8.68m

Price to Sales Ratio vs Peers

How does ATORX BTU's PS Ratio compare to its peers?

The above table shows the PS ratio for ATORX BTU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average17.8x
APTA Aptahem
6.1xn/aSEK 15.3m
LPGO Lipigon Pharmaceuticals
n/a134.67%SEK 908.9k
PROGEN Prostatype Genomics
46.8xn/aSEK 27.8m
EXPRS2 ExpreS2ion Biotech Holding
0.3x23.58%SEK 5.5m
ATORX BTU Alligator Bioscience
0.2x-17.92%SEK 8.7m

Price-To-Sales vs Peers: ATORX BTU is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (21.6x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does ATORX BTU's PS Ratio compare vs other companies in the SE Biotechs Industry?

11 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.10.8x13.2%
ATORX BTU Alligator Bioscience
 0.2x-17.92%US$943.03k
CANTA Cantargia
1.7x-47.92%US$57.00m
SPRINT Sprint Bioscience
2.5x3.56%US$41.21m
ATORX BTU 0.2xIndustry Avg. 10.8xNo. of Companies10PS01224364860+
11 CompaniesEstimated GrowthMarket Cap
Industry Avg.10.8x33.7%
ATORX BTU Alligator Bioscience
 0.2x32.59%US$943.03k
No more companies

Price-To-Sales vs Industry: ATORX BTU is good value based on its Price-To-Sales Ratio (0.2x) compared to the Swedish Biotechs industry average (7.8x).

Price to Sales Ratio vs Fair Ratio

What is ATORX BTU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ATORX BTU PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ATORX BTU's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

SEK 1.47
Fair Value
71.7% undervalued intrinsic discount
1
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/15 03:55
End of Day Share Price 2026/01/13 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alligator Bioscience AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carl RamaniusRedeye
Filip LindkvistRedeye